Multiple Myeloma Support + Trials

What's the purpose of this trial?

The goal of this clinical trial is to evaluate the best dose, safety and effectiveness of elranatamab when combined with different anti-cancer therapies in participants with multiple myeloma.

This trial is currently open and accepting patients.

What will happen during the trial?

This clinical trial is being conducted in several different sub-studies. This trial is open-label, which means that participants and the study team will know which part participants are enrolled in, and which drugs / doses they will be receiving. Two sub-studies are currently open and enrolling participants.

After the end of the study, researchers may ask you to have monthly follow up visits, or telephone calls with the study team every few months.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

have measurable multiple myeloma as determined by the trial protocol.
have multiple myeloma that is refractory to at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD-38 antibody.
do not have primary refractory multiple myeloma.
have received at least three prior lines of therapy for multiple myeloma.
have not previously received either an anti-BCMA bispecific antibody or any kind of therapy targeting BCMA depending on the sub-study currently open (BCMA is the target of the combination of drugs tested against multiple myeloma).
have adequate heart, liver, kidney and bone marrow function as described in the trial criteria.